{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZOTS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/906ac168-9b6d-475e-9b73-3964f83d88a9/"}]}}, {"id": "source:356b9804c9a950cf8dc50d3ef8ffae3b5a2bb261fcdebe7b7d66a4ec0cf11c6d", "url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "title": "Zoetis (ZTS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on a reported basis and a 1% decline on an organic operational basis driven by a 1% decrease in volume.Adjusted Net Income -- $781 million, declining 2% on an organic operational basis.Adjusted Diluted EPS -- $1.87, representing 4% growth year over year and benefiting from a lower share count.U.S. Segment Revenue ", "date_published": "2026-08-13T12:01:05+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ZOTS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/906ac168-9b6d-475e-9b73-3964f83d88a9/"}]}}, {"id": "source:cdf3e81e3e1d64cf511869724799f19ad9e7b4dba243ff614838644ad8305a86", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPNzA5S3RBWHoxVXMtUUxLY01oTWRPNWh4ZWFuQ3RqUVctejZVRTc3clZVdkNIMlFDdWhGWGZSVFNoeFFUWmJGQXdUZEN2N0RVbU1DWDZOLWgxRGwwTEpZWDd5TnVobU5vM2dTbnVNZW9tNEN2aTQ0VnJVZkdhSWZPU3RYYUR5bkcxU3lSQWROSnUtYUN0MXhxN1NiMTloMU5ITVJ1eHlMZHhxNWF5R1ZWTUF5b25zRDBwR2tlNHYzcFVvbXFfbFFockNDVG4zZndUdGEtQ2FDb2FRQS1lSFhkYk12RTNmMC02bXBIanBPcGJXWjFjVXNDeVY2eXQtUdIB_gFBVV95cUxPNzA5S3RBWHoxVXMtUUxLY01oTWRPNWh4ZWFuQ3RqUVctejZVRTc3clZVdkNIMlFDdWhGWGZSVFNoeFFUWmJGQXdUZEN2N0RVbU1DWDZOLWgxRGwwTEpZWDd5TnVobU5vM2dTbnVNZW9tNEN2aTQ0VnJVZkdhSWZPU3RYYUR5bkcxU3lSQWROSnUtYUN0MXhxN1NiMTloMU5ITVJ1eHlMZHhxNWF5R1ZWTUF5b25zRDBwR2tlNHYzcFVvbXFfbFFockNDVG4zZndUdGEtQ2FDb2FRQS1lSFhkYk12RTNmMC02bXBIanBPcGJXWjFjVXNDeVY2eXQtUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxPNzA5S3RBWHoxVXMtUUxLY01oTWRPNWh4ZWFuQ3RqUVctejZVRTc3clZVdkNIMlFDdWhGWGZSVFNoeFFUWmJGQXdUZEN2N0RVbU1DWDZOLWgxRGwwTEpZWDd5TnVobU5vM2dTbnVNZW9tNEN2aTQ0VnJVZkdhSWZPU3RYYUR5bkcxU3lSQWROSnUtYUN0MXhxN1NiMTloMU5ITVJ1eHlMZHhxNWF5R1ZWTUF5b25zRDBwR2tlNHYzcFVvbXFfbFFockNDVG4zZndUdGEtQ2FDb2FRQS1lSFhkYk12RTNmMC02bXBIanBPcGJXWjFjVXNDeVY2eXQtUdIB_gFBVV95cUxPNzA5S3RBWHoxVXMtUUxLY01oTWRPNWh4ZWFuQ3RqUVctejZVRTc3clZVdkNIMlFDdWhGWGZSVFNoeFFUWmJGQXdUZEN2N0RVbU1DWDZOLWgxRGwwTEpZWDd5TnVobU5vM2dTbnVNZW9tNEN2aTQ0VnJVZkdhSWZPU3RYYUR5bkcxU3lSQWROSnUtYUN0MXhxN1NiMTloMU5ITVJ1eHlMZHhxNWF5R1ZWTUF5b25zRDBwR2tlNHYzcFVvbXFfbFFockNDVG4zZndUdGEtQ2FDb2FRQS1lSFhkYk12RTNmMC02bXBIanBPcGJXWjFjVXNDeVY2eXQtUQ?oc=5", "title": "Teva (TEVA) legt um 6,0 % zu, nachdem Moody\u2019s das Rating auf \u201eInvestment Grade\u201c angehoben und die Prognose f\u00fcr 2026 nach oben korrigiert hat", "content_text": "Teva (TEVA) legt um 6,0 % zu, nachdem Moody\u2019s das Rating auf \u201eInvestment Grade\u201c angehoben und die Prognose f\u00fcr 2026 nach oben korrigiert hat", "date_published": "2026-08-12T08:02:25+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Analyst action", "TEVA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TEVA", "name": "Teva Pharmaceutical Industries Limited", "sentiment_url": "https://sharemaestro.com/sentiment/a9a43a0e-ccc7-4068-9887-6f0965c228b1/"}]}}, {"id": "source:f74d3d00d31114121650669e3642ab0df9485f73143469998082c7037d1add2e", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBVMVdJWWJhTV9xYUtVRXBQcHI3RFJLOURxZmg1c2xvdVY4UjhaNWN2UmxiUC1mb0RGMFJqVUZxcjBxdERkZFFGcGo0c3pyeUdTNWVLWWp1bTlKQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBVMVdJWWJhTV9xYUtVRXBQcHI3RFJLOURxZmg1c2xvdVY4UjhaNWN2UmxiUC1mb0RGMFJqVUZxcjBxdERkZFFGcGo0c3pyeUdTNWVLWWp1bTlKQQ?oc=5", "title": "TEVA PHARMACEUTICAL INDUSTRIES AKTIE: AI-Analysen, Prognose & Kursziel", "content_text": "TEVA PHARMACEUTICAL INDUSTRIES AKTIE: AI-Analysen, Prognose & Kursziel", "date_published": "2026-08-10T20:31:49+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "TEVA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TEVA", "name": "Teva Pharmaceutical Industries Limited", "sentiment_url": "https://sharemaestro.com/sentiment/a9a43a0e-ccc7-4068-9887-6f0965c228b1/"}]}}, {"id": "source:b79dfef99e14f83e6e7485a496aba4a45ab4c2e909ab425d2433d0cf424e054a", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "title": "Zoetis Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand offset growth in livestock, diagnostics and international markets. Pet-care pressures led to a lowered outlook. Declining veterinary visits, selective pet-owner spending and increased competition hurt companion-animal and dermatology sales; Zoetis now expects full-year organic operational revenue to decline 3%", "date_published": "2026-08-09T18:03:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZOTS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/906ac168-9b6d-475e-9b73-3964f83d88a9/"}]}}, {"id": "source:8118c2f67dfe134f758541351d31005441763660777ef4bbb0d6828fb4458168", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWlJKdERWQkxJRDROdHhyOWg3Nnc1QVRPVkVRUFlMQm1paUdNTUp3VndhbFhmSFRnTm1TZG5FVl9EeDQxalpnOTRocnZaTWEtWGVsOXRMT0RacU1RUGN0bkF0MjNUOWxHcHJwdFNxbHo1QnVjV1BRT3dqbE9fZk5iekxmTTBBU0U1Tm9LbjF3MTFnMzJKMktIR1drUXpPV203WU9SYkJCRnNUOThzN2FuYTlhT2JXZWZrUGNqdG9QMm9pMU0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWlJKdERWQkxJRDROdHhyOWg3Nnc1QVRPVkVRUFlMQm1paUdNTUp3VndhbFhmSFRnTm1TZG5FVl9EeDQxalpnOTRocnZaTWEtWGVsOXRMT0RacU1RUGN0bkF0MjNUOWxHcHJwdFNxbHo1QnVjV1BRT3dqbE9fZk5iekxmTTBBU0U1Tm9LbjF3MTFnMzJKMktIR1drUXpPV203WU9SYkJCRnNUOThzN2FuYTlhT2JXZWZrUGNqdG9QMm9pMU0?oc=5", "title": "Zoetis Inc. passt Gewinnprognose f\u00fcr das Gesamtjahr 2026 an", "content_text": "Zoetis Inc. passt Gewinnprognose f\u00fcr das Gesamtjahr 2026 an", "date_published": "2026-08-06T12:36:46+00:00", "authors": [{"name": "MarketScreener Schweiz"}], "tags": ["Market update", "ZOTS"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZOTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/906ac168-9b6d-475e-9b73-3964f83d88a9/"}]}}, {"id": "source:c9a311c2a1a2427478a0480a8e36e2ce5bdd419518d361e5a37e25937f27896b", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1wUnJrVmpVV0FpQ09sZ2FqU1AyVWtPTElERUhPeG1TV0EzZHVsTVNzVDNkNjdXeGhxUmFJMzhMZmEzVUpOUVNVcEU2Wm9XTk8wVTVnMVUtai1QSjJMMHVCaExUajRHTGs2THc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1wUnJrVmpVV0FpQ09sZ2FqU1AyVWtPTElERUhPeG1TV0EzZHVsTVNzVDNkNjdXeGhxUmFJMzhMZmEzVUpOUVNVcEU2Wm9XTk8wVTVnMVUtai1QSjJMMHVCaExUajRHTGs2THc?oc=5", "title": "Teva Pharmaceutical Industries Ltd (TEVA) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Teva Pharmaceutical Industries Ltd (TEVA) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "TEVA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TEVA", "name": "Teva Pharmaceutical Industries Limited", "sentiment_url": "https://sharemaestro.com/sentiment/a9a43a0e-ccc7-4068-9887-6f0965c228b1/"}]}}, {"id": "source:0f168cee8ddd7543b3508150815502a1912d047e7a593b2edcedcfe1b226ef4c", "url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTE5ha2s3eGNNZ2Y5UnJkb2RMVzVxaTZTZF9rUUQwUGlEVFhRdVdlN3pKWWhwMm93SDJyNkQyVnZJZE00aTZNa1ViXzVJUnBDRTlsUnBCamwyd1M5TWMyUXc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTE5ha2s3eGNNZ2Y5UnJkb2RMVzVxaTZTZF9rUUQwUGlEVFhRdVdlN3pKWWhwMm93SDJyNkQyVnZJZE00aTZNa1ViXzVJUnBDRTlsUnBCamwyd1M5TWMyUXc?oc=5", "title": "TEVA|Teva Pharmaceutical Industries Ltd|Kurs:36.480|\u00c4nderung %:+0.340", "content_text": "TEVA|Teva Pharmaceutical Industries Ltd|Kurs:36.480|\u00c4nderung %:+0.340", "date_published": "2026-07-25T08:30:57+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "TEVA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TEVA", "name": "Teva Pharmaceutical Industries Limited", "sentiment_url": "https://sharemaestro.com/sentiment/a9a43a0e-ccc7-4068-9887-6f0965c228b1/"}]}}]}